Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT in children with ASD
NCT03426826Phase 1Active, not recruiting
- Sponsor
- Children's Hospital Los Angeles
- Start
- Aug 2019
- Primary completion
- Mar 2026
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of allogeneic fecal microbiota in Autism Spectrum Disorder (ASD), sponsored by Children's Hospital Los Angeles. Primary endpoint: Safety and tolerability at 24 weeks. Started Aug 2019; status: active, not recruiting.
02
Drugs
allogeneic fecal microbiota
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT03426826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03426826.